Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBT-100
- Development stage
- Unknown
- Lead developer
- Singh Biotechnology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
SBT-100 is a cell-penetrating single-domain antibody (sdAb) from Singh Biotechnology that binds KRAS and inhibits growth of human cancers with KRAS activating mutations (AACR 2019 abstract 1544, Cancer Research 79(13 Suppl)).
- Other names
- SON-101SON101SON 101
02
Targets
KRAS (Kirsten rat sarcoma viral oncogene homolog)STAT1 (Signal transducer and activator of transcription protein 1)STAT3 (Signal Transducer and Activator of Transcription 3)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on SBT-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBT-100.